Rock Springs Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Rock Springs Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$305K	Sell	21,062 -1,908,869	-99%	-$27.4M	0.02%	98
2025 Q4	$27.5M	Sell	1,929,931 -17,443	-0.9%	-$171K	1.41%	24
2025 Q3	$15.3M	Sell	1,947,374 -12,960	-0.7%	-$92.2K	0.9%	40
2025 Q2	$11.2M	Buy	1,960,334 +50,972	+3%	+$329K	0.7%	49
2025 Q1	$15.6M	Sell	1,909,362 -690,063	-27%	-$6.39M	0.89%	41
2024 Q4	$24.5M	Buy	2,599,425 +1,349,145	+108%	+$14M	0.93%	37
2024 Q3	$13.4M	Buy	1,250,280 +31,700	+3%	+$345K	0.43%	59
2024 Q2	$12.1M	Buy	1,218,580 +65,924	+6%	+$677K	0.36%	66
2024 Q1	$13.6M	Buy	1,152,656 +88,850	+8%	+$1.14M	0.34%	69
2023 Q4	$15.1M	Hold	1,063,806	–	–	0.37%	64
2023 Q3	$12.9M	Hold	1,063,806	–	–	0.35%	66
2023 Q2	$13.4M	Hold	1,063,806	–	–	0.32%	70
2023 Q1	$11.8M	Hold	1,063,806	–	–	0.28%	72
2022 Q4	$13M	Buy	1,063,806 +51,300	+5%	+$578K	0.31%	69
2022 Q3	$10.6M	Hold	1,012,506	–	–	0.27%	77
2022 Q2	$10.9M	Hold	1,012,506	–	–	0.32%	75
2022 Q1	$9.59M	Hold	1,012,506	–	–	0.24%	82
2021 Q4	$11.7M	Hold	1,012,506	–	–	0.27%	86
2021 Q3	$9.67M	Hold	1,012,506	–	–	0.2%	108
2021 Q2	$9.76M	Hold	1,012,506	–	–	0.19%	117
2021 Q1	$10M	Sell	1,012,506 -16,494	-2%	-$255K	0.22%	116
2020 Q4	$23.8M	Buy	1,029,000 +5,179	+0.5%	+$106K	0.5%	71
2020 Q3	$14.5M	Buy	1,023,821 +7,000	+0.7%	+$102K	0.37%	82
2020 Q2	$15.3M	Buy	1,016,821 +16,821	+2%	+$205K	0.42%	80
2020 Q1	$9.24M	Hold	1,000,000	–	–	0.38%	78
2019 Q4	$9.74M	Hold	1,000,000	–	–	0.31%	86
2019 Q3	$8.02M	Hold	1,000,000	–	–	0.32%	83
2019 Q2	$12.5M	Hold	1,000,000	–	–	0.45%	73
2019 Q1	$13.6M	Hold	1,000,000	–	–	0.52%	64
2018 Q4	$9.58M	Hold	1,000,000	–	–	0.45%	73
2018 Q3	$12.1M	Hold	1,000,000	–	–	0.44%	75
2018 Q2	$15.6M	Hold	1,000,000	–	–	0.6%	63
2018 Q1	$15M	Buy	1,000,000 +90,000	+10%	+$1.37M	0.64%	57
2017 Q4	$13.1M	Hold	910,000	–	–	0.59%	61
2017 Q3	$13.7M	Buy	910,000 +152,500	+20%	+$2.02M	0.63%	54
2017 Q2	$7.63M	Hold	757,500	–	–	0.39%	80
2017 Q1	$5.4M	Hold	757,500	–	–	0.31%	87
2016 Q4	$3.77M	Buy	757,500 +62,500	+9%	+$433K	0.25%	89
2016 Q3	$5.14M	Buy	695,000 +15,000	+2%	+$101K	0.32%	87
2016 Q2	$3.71M	Buy	680,000 +66,500	+11%	+$465K	0.27%	95
2016 Q1	$5.18M	Buy	613,500 +47,000	+8%	+$333K	0.43%	76
2015 Q4	$5.5M	Buy	566,500 +111,500	+25%	+$1M	0.42%	80
2015 Q3	$6.37M	Buy	455,000 +77,500	+21%	+$1.22M	0.52%	68
2015 Q2	$5.34M	Buy	+377,500	New	+$4.54M	0.39%	83

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rock Springs Capital Management's FOLD Position: Q1 2026 in Review

Rock Springs Capital Management reduced its Amicus Therapeutics (FOLD) stake by 99% in Q1 2026, selling an estimated $27.4M and leaving 21,062 shares worth $305K. The position accounts for 0.02% of the portfolio, ranked #98.

Rock Springs Capital Management first reported a position in FOLD in Q2 2015 and has held it in 44 quarters since. The position peaked at $27.5M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Rock Springs Capital Management held 21,062 shares of Amicus Therapeutics worth $305K as of Q1 2026.
Rock Springs Capital Management sold 1,908,869 Amicus Therapeutics shares in Q1 2026, an estimated $27.4M.
Amicus Therapeutics made up 0.02% of Rock Springs Capital Management's portfolio in Q1 2026, its #98 holding.
Rock Springs Capital Management first reported a position in Amicus Therapeutics in Q2 2015 and has held it in 44 quarters since.
Rock Springs Capital Management's Amicus Therapeutics position peaked at $27.5M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.